Leukemia Therapeutics Market Share, Size, Demand, Trends And Forecast 2030

Leukemia Therapeutics Market- By Treatment Type, By Type of Leukemia, By Molecule Type – Regional Outlook, Competitive Strategies, and Segment Forecasts to 2030

Published: Oct-2022	Report ID: HLCA2210	Pages: 1 - 208	Formats^*:
Category : Healthcare

Global Leukemia Therapeutics Market Overview

According to SPER Market Research, the Global Leukemia Therapeutics Market is estimated to reach USD 35.96 billion by 2030 with a CAGR of 11.3%.

Leukemia is a type of blood cancer that affects the bone marrow and lymphatic system. It affects leucocytes, or white blood cells, as the name implies. The DNA of leucocytes is broken in this type of cancer, causing them to proliferate and divide uncontrollably. These cells continue to develop and accumulate, preventing healthy white blood cells from forming and functioning.

Leukemia can be acute or chronic, affecting both red blood cells and platelets. Fever, night sweats, weight loss, an enlarged liver, frequent infections, and swollen lymph nodes are all common symptoms of leukemia. Some of the numerous kinds of leukemia are acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia. Acute myeloid leukemia, also known as acute myelogenous leukemia, is most common in adults.

Because of the increased number of people suffering from leukemia, technical improvements and breakthroughs in the field of blood cancer testing are driving the Global Leukemia Therapeutics Market. Furthermore, rising public awareness about the importance of preventive healthcare is likely to drive the market throughout the forecast period. Government initiatives and policies encouraging cancer awareness are expected to drive market expansion until 2026.

Impact of COVID-19 on the Global Leukemia Therapeutics Market

The risk of infection is low in treating Leukemia during COVID-19 times. Although the mortality rate maybe be higher in patients with leukemia and COVID-19. Furthermore, according to the study "Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicentre Study During the COVID-19 Outbreak," published in Cancer Discovery in June 2021, the risk of severe COVID-19 infection was found to be higher, at around 57 percent, among patients with blood cancers.

Get more information on this report: Download Free Sample PDF

Scope of the Report:

Report Metric	Details
Market size available for years	2019-2030
Base year considered	2021
Forecast period	2022-2030
Segments covered	By Treatment Type, By Type of Leukemia, By Molecule Type
Geographies covered	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered	AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company Ltd., Gilead Sciences Inc. ICell Gene therapeutics, Merck & Company Inc., Novartis AG, Otsuka Holdings Company Ltd., Pfizer Inc., Roche HoldingAG, Stemline Therapeutics Inc., Takeda Pharmaceutical Company Ltd.

Global Leukemia Therapeutics Market, By Treatment Type:

Based on the Treatment Type, Global Leukemia Therapeutics Market is segmented as; Chemotherapy, Immunotherapy, Targeted Therapy, and Other Treatments

Global Leukemia Therapeutics Market, By Type of Leukemia:

Based on the Type of Leukemia, Global Leukemia Therapeutics Market is segmented as; Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, and Other Type of Leukemias.

Global Leukemia Therapeutics Market, By Molecule Type:

Based on the Molecule Type, Global Leukemia Therapeutics Market is segmented as; Small Molecules and Biologics.

Global Leukemia Therapeutics Market, By Region:

The Asia Pacific emerged as the leading region in the Global Leukemia Therapeutics Market with the maximum market share in 2021.

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source

2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPERâ€™s internal database
2.1.4 Premium insight from KOLâ€™s

2.2 Market size estimation

2.2.1 Top-down and Bottom-up approach

2.3 Data Triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity, and Challenges Analysis

4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges

4.2. COVID-19 Impacts on the Global Leukemia Therapeutics Market

5. Market variables and outlook

5.1. SWOT analysis

5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats

5.2. PESTEL analysis

5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape

5.3. PORTERâ€™S five forces analysis

5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry

5.4. Heat map analysis

6. Global Leukemia Therapeutics Market, By Treatment Type, 2019-2030 (USD Million)

6.1. Chemotherapy
6.2. Immunotherapy
6.3. Targeted Therapy
6.4. Other Treatments

7. Global Leukemia Therapeutics Market, By Type of Leukemia, 2019-2030(USD Million)

7.1. Acute Lymphocytic Leukemia
7.2. Acute Myeloid Leukemia
7.3. Chronic Lymphocytic Leukemia
7.4. Chronic Myeloid Leukemia
7.5. Other Type of Leukemias

8. Global Leukemia Therapeutics Market, By Molecule Type, 2019-2030 (USD Million)

8.1. Small Molecules
8.2. Biologics

9. Global Leukemia Therapeutics Market, By Region, 2019-2030 (USD Million)

9.1. North America

9.1.1. United States
9.1.2. Canada
9.1.3. Mexico

9.2. Europe

9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific

9.4. South America

9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America

9.5. Middle East & Africa

9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa

10. Company Profiles

10.1 AbbVie Inc.

10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments

10.2 Amgen Inc.

10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments

10.3 Astellas Pharma Inc.

10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments

10.4 AstraZeneca PLC

10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments

10.5 Bristol-Myers Squibb Company

10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments

10.6 Eli Lilly and Company Ltd.

10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments

10.7 Gilead Sciences Inc.

10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments

10.8 iCell Gene therapeutics

10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments

10.9 Merck & Company Inc.

10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments

10.10 Novartis AG

10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments

10.11 Otsuka Holdings Company Ltd.

10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments

10.12 Pfizer Inc.

10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments

10.13 Roche Holding AG

10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments

10.14 Sanofi

10.14.1. Company details
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments

10.15 Stemline Therapeutics Inc.

10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments

10.16 Takeda Pharmaceutical Company Ltd.

10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent developments

â€ƒ

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1